Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study
- 1 December 1999
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (18) , 2547-2554
- https://doi.org/10.1097/00002030-199912240-00008
Abstract
To compare the initiation of highly active antiretroviral therapy (HAART) in HIV-infected patients according to sex, route of HIV acquisition and education, and to assess the impact of differences in utilization on the probability of progression to AIDS.Keywords
This publication has 17 references indexed in Scilit:
- Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatmentAIDS, 1998
- Self-reported Antiretroviral Therapy in Injection Drug UsersJAMA, 1998
- 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1998
- Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 diseaseThe Lancet, 1998
- Hidden dangers of incompletely suppressive antiretroviral therapyThe Lancet, 1997
- Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarctionThe Lancet, 1996
- Time to Hit HIV, Early and HardNew England Journal of Medicine, 1995
- Differences in progression of HIV infection between men and womenBMJ, 1995
- The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristicsInternational Journal of Public Health, 1994
- Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban CommunityNew England Journal of Medicine, 1994